# Constipation on GLP-1 tablets: why the formulation matters

Tablets can still cause constipation. The exact product and postpartum factors help explain what needs review.

Canonical: https://velri.co/blog/glp1-constipation-week-three-oral-postpartum-what-to-expect
Publisher: Velri (https://velri.co/about)
Published: 2026-07-30
Updated: 2026-09-30
Editorial policy: https://velri.co/editorial-policy

Taking a GLP-1 medicine by mouth does not remove its digestive side effects. The approved semaglutide weight-management tablet label includes constipation among reported adverse reactions. Symptoms can occur with tablets as well as injections. [1]

If constipation starts a few weeks into treatment, the important questions are which product you are taking, how bowel function has changed and whether there are other contributors.

## “Oral” does not identify the product

There is an FDA-approved semaglutide tablet for weight management. A compounded oral preparation is a different product and is not FDA approved. The FDA does not evaluate compounded drugs for safety, effectiveness or quality before marketing. [1][2]

The approved tablet's evidence and instructions should not automatically be applied to a compounded formulation. The label on the actual prescription should make the ingredient and preparation clear. [1][2]

## Why the postpartum history matters

Constipation can involve hard stools, difficulty passing them or incomplete emptying, not just fewer bowel movements. Iron supplements, some pain medicines, changes in eating and drinking, and pelvic-floor disorders are among recognized contributors. [3]

Those details may be relevant after childbirth. They can also overlap with medication-related constipation, so attributing the entire problem to one cause may miss useful information. [1][3]

Breastfeeding needs a separate product review. The approved tablet label does not recommend breastfeeding during tablet treatment. The formulation therefore matters for more than the choice between a pill and an injection. [1]

## What makes symptoms concerning

A useful update describes stool consistency, pain, fluid intake, other medicines and whether symptoms are worsening. [3]

Constant abdominal pain, vomiting, inability to pass gas, fever or blood in the stool requires prompt medical assessment. Persistent symptoms also merit a review, even without those warning signs. [3]

The next step should address the actual bowel problem and the complete postpartum context. General constipation care may include changes in food, fluids and activity, while medication decisions belong with the clinician reviewing the prescription. [4]

## Sources
[1] DailyMed - WEGOVY- semaglutide injection, solution
WEGOVY- semaglutide tablet (2026). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
[2] Compounding and the FDA: Questions and Answers | FDA (2025). https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
[3] Symptoms & Causes of Constipation - NIDDK (2018). https://www.niddk.nih.gov/health-information/digestive-diseases/constipation/symptoms-causes
[4] Treatment for Constipation - NIDDK (2018). https://www.niddk.nih.gov/health-information/digestive-diseases/constipation/treatment

## About this information
General health information, not personal medical advice, diagnosis or treatment. A prescription is required and is never guaranteed.
Velri is a brand operated by Velri Management LLC, a Nevada limited liability company. Velri is a non-clinical technology and administrative services company. Velri does not provide medical advice, diagnosis, treatment, or pharmacy services, and does not direct the clinical judgment of any provider.
All medical consultations and prescriptions are provided directly by independent provider groups (Online Medical Care, P.C.; TMD of Kansas, P.A.; TMD of Texas, P.A.; and TMD of CA, PC), by a provider licensed in your state. Velri does not employ providers. A prescription is issued only if a provider determines it is clinically appropriate in their independent medical judgment.
All prescription products are dispensed by independent, licensed pharmacies. Velri does not own, operate, or control any pharmacy and does not dispense medication. You may opt out of using a given provider group or pharmacy at any time.
Compounded medications are not reviewed or approved by the FDA for safety, effectiveness, or quality. Compounded products are not equivalent to or interchangeable with any FDA-approved brand-name drug. Availability varies by state.
Velri is cash-pay. We do not bill Medicare, Medicaid, or commercial insurance. Refunds and order problems are addressed in the Terms of Use; your rights under applicable law are not limited. State availability and clinical eligibility apply.
Velri and telehealth are not for medical emergencies. If you are experiencing an emergency, call 911.
These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.
Care is available to eligible adults 18 and older in 47 states and D.C., United States only.
Notice of Privacy Practices: https://velri.co/privacy/notice-of-privacy-practices
Terms: https://velri.co/legal/terms
Provider group or pharmacy opt-out help: https://velri.co/contact and https://velri.co/standards#trust-support